Droperidol is associated with reduced length of stay in the treatment of cannabinoid hyperemesis syndrome by Geoffrey S. Kelly (21537766)

“…After adjustments, droperidol use was associated with a reduced length of stay (mean ratio 0.76; 95% CI: 0.62 0.94; <i>P</i> = 0.01), decreased total medication administration (OR 0.34; 95% CI: 0.20–0.58; <i>P <</i>0.001) and decreased usage of opioids (OR 0.16; 95% CI: 0.07–0.39; <i>P <</i>0.001). …”

Forest plots comparing demographic factors within SARS-CoV-2 variant waves. by Rebecca M. Cantu (19787070)

“…Confidence intervals that do not cross 1 on the x-axis are considered significant, with higher numbers associated with increased chances for hospitalization and lower numbers with decreased chances for hospitalization.…”

CCDC66 localizes to the axoneme and regulates primary cilium stability but not cilia formation in IMCD3 cells. by Jovana Deretic (13113617)

“…<i>n</i> > 600 cells for control and >400 cells for CCDC66 depletion. The mean cilia length in CCDC66-depleted cells decreased to 0.67-fold compared to the mean control length. …”

Table 1_Effects of a community pharmacy-based structured medication review on drug-related problems in all-comers with polypharmacy: a randomized, controlled, double-blind, paralle... by Thorsten Bischof (19848696)

“…Therapy adherence- and health literacy-related DRPs decreased significantly by ~60% and ~64%, respectively. …”

Data (F. Ghasemian).sav by Mona Rahnavardi (21220424)

“…A P<0.05 was considered significant.</p><p dir="ltr">Results: Data analysis showed that the mean score of maternal lifestyle and antenatal anxiety was</p><p dir="ltr">67.8 ± 10.9 and 43.2 ± 20.1, respectively. …”

Data Sheet 1_Listening to mom in the neonatal intensive care unit: a randomized trial of increased maternal speech exposure on white matter connectivity in infants born preterm.pdf by Katherine E. Travis (6680396)

“…We hypothesized that neonates randomized to the T-group would show evidence for increased maturation within the arcuate, indexed as decreased MD and increased FA and R1, compared to neonates in the C-group.…”

Data Sheet 1_GBD: incidence rates and prevalence of anxiety disorders, depression and schizophrenia in countries with different SDI levels, 1990–2021.pdf by Jueqi Wang (21376073)

“…</p>Results<p>In countries with different SDI levels, the age-standardized average annual percentage change (AAPC) in the incidence of anxiety were all shown to be increasing, and there were large gender differences between the different SDI levels, with a maximum of 0.97 (0.76–1.18) for females in countries with a high SDI level, Age-standardized more rates per 100,000 people in high SDI countries, from 658.87 in 1990 to 841.56 in 2021, and the largest gender differences in countries with a low to moderate SDI level, with AAPCs for males and females of 0.04 (0.04–0.05), 0.86 (0.63–1.09); for depression, only the countries with medium-high SDI levels were statistically significant compared to the countries with medium-low SDI levels, with AAPCs of 0.05 (0.04–0.07), 0.04 (0.04–0.05); for schizophrenia in addition to the AAPCs of the countries with medium-high SDI levels showed an increase of 0.16 (0.13–0.18); the rest decreased.…”

Table 1_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

“…Identification of regions with the largest potential for reducing HHD burden relative to their SDI peers. …”

Table 4_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

“…Identification of regions with the largest potential for reducing HHD burden relative to their SDI peers. …”

Image 1_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.tif by Ning An (618997)

“…Identification of regions with the largest potential for reducing HHD burden relative to their SDI peers. …”

Table 3_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

“…Identification of regions with the largest potential for reducing HHD burden relative to their SDI peers. …”

Table 2_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

“…Identification of regions with the largest potential for reducing HHD burden relative to their SDI peers. …”

Image 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”

Table 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”

Image 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”

Table 7_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”

Table 6_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”

Table 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”

Table 4_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”

Table 3_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

“…CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”